Clinical Research

Association of lipid variability with adverse cardiovascular events in STEMI patients after emergency percutaneous coronary intervention

  • Wei XIE ,
  • Zhenqi. SU
Expand
  • Cardiovascular Department of Huaibei Miner General Hospital,Huaibei 235000,China

Received date: 2024-03-01

  Online published: 2024-07-30

Abstract

Objective Exploring the predictive value of blood lipid variability for adverse cardiovascular events in patients with acute ST segment elevation myocardial infarction (STEMI) after emergency percutaneous coronary intervention (PCI). Methods A total of 235 STEMI patients who underwent emergency PCI in our hospital from October 2020 to October 2022 were selected as the research objects. According to whether target lesion failure (TLF) occurred, the patients were divided into TLF group and control group Lipid variability [standard deviation (SD), coefficient of variation (CV) and mean-independent coefficient of variation (VIM)] of the two groups were compared. Multivariate Cox regression analysis was used to explore the related factors of TLF in STEMI patients after emergency PCI, and receiver operating characteristic curve (ROC) was used to analyze the predictive value. Results Variability indexes of low-density lipoprotein (LDL), high-density lipoprotein (HDL) and lipoprotein a[LP(a)] in TLF group: LDL (SD), LDL (CV), LDL (VIM), HDL (SD), HDL (CV), HDL (VIM), LP(a) (SD), LP(a) (CV), LP(a) (CV) a) (VIM) were higher than those in control group, and the differences were statistically significant (P < 0.05). The results of multivariate Cox regression analysis showed that LDL (SD), LDL (CV), LDL (VIM), HDL (SD), HDL (CV), HDL (VIM), LP(a) (SD), LP(a) (CV), LP(a) (VIM) were all risk factors for TLF in STEMI patients after emergency PCI (P < 0.05). ROC curve analysis results showed that, LDL (SD), LDL (CV), LDL (VIM), HDL (SD), HDL (CV), HDL (VIM), LP(a) (SD), LP(a) (CV), LP(a) (VIM) have certain predictive value for TLF in STEMI patients after emergency PCI(AUC: 0.790, 0.805, 0.833, 0.766, 0.795, 0.816, 0.773, 0.782, 0.798). Conclusion Lipid variability is associated with adverse cardiovascular events in STEMI patients after emergency PCI, and is an independent risk factor for TLF in STEMI patients after emergency PCI.

Cite this article

Wei XIE , Zhenqi. SU . Association of lipid variability with adverse cardiovascular events in STEMI patients after emergency percutaneous coronary intervention[J]. The Journal of Practical Medicine, 2024 , 40(15) : 2121 -2125 . DOI: 10.3969/j.issn.1006-5725.2024.15.013

References

1 SAITO Y, OYAMA K, TSUJITA K, et al. Treatment strategies of acute myocardial infarction: updates on revascularization, pharmacological therapy, and beyond[J]. J Cardiol, 2023, 81(2):168-178. doi:10.1016/j.jjcc.2022.07.003
2 LI S, GAO X, YANG J, et al. Number of standard modifiable risk factors and mortality in patients with first-presentation ST-segment elevation myocardial infarction: insights from China Acute Myocardial Infarction registry[J]. BMC Med, 2022, 20(1):217. doi:10.1186/s12916-022-02418-w
3 SHAH T, KAPADIA S, LANSKY A J, et al. ST-segment elevation myocardial infarction: sex differences in incidence, etiology, treatment, and outcomes [J]. Curr Cardiol Rep, 2022, 24(5):529-540. doi:10.1007/s11886-022-01676-7
4 ELENDU C, AMAECHI D C, ELENDU T C, et al. Comprehensive review of ST-segment elevation myocardial infarction: Understanding pathophysiology, diagnostic strategies, and current treatment approaches[J]. Medicine (Baltimore), 2023, 102(43):e35687. doi:10.1097/md.0000000000035687
5 TRUESDELL A G, ALASNAG M A, KAUL P, et al. Intravascular imaging during percutaneous coronary intervention: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2023, 81(6):590-605. doi:10.1016/j.jacc.2022.11.045
6 芮淑红,王晨芳,李云贺,等. 吲哚布芬联合氯吡格雷对急性冠脉综合征患者血管内皮功能、炎性因子、氧化应激的影响[J].实用医学杂志,2023,39(12):1551-1555. doi:10.3969/j.issn.1006-5725.2023.12.016
7 PROTTY M, SHARP A S P, GALLAGHER S, et al. Defining percutaneous coronary intervention complexity and risk: an analysis of the United Kingdom BCIS database 2006-2016[J]. JACC Cardiovasc Interv, 2022, 15(1):39-49. doi:10.1016/j.jcin.2021.09.039
8 KHURANA K V, RANJAN A. ST-segment elevation in conditions of non-cardiovascular origin mimicking an acute myocardial infarction: a narrative review[J]. Cureus, 2022, 14(10):e30868.
9 MASROURI S, CHERAGHI L, DERAVI N, et al. Mean versus variability of lipid measurements over 6 years and incident cardiovascular events: More than a decade follow-up[J]. Front Cardiovasc Med, 2022, 9:1065528. doi:10.3389/fcvm.2022.1065528
10 DONG L, TONG J, FAN S. Association between the serum lipoprotein-associated phospholipase A2 level and acute coronary syndrome[J]. Cardiovasc J Afr, 2023, 34:1-5. doi:10.5830/cvja-2022-056
11 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志,2019,47(10):766-783. doi:10.3760/cma.j.issn.0253-3758.2019.10.003
12 FRANK M, SANDERS C, BERRY B P. Evaluation and management of ST-segment elevation myocardial infarction in the emergency department[J]. Emerg Med Pract, 2021, 23(1):1-28.
13 王晓敏,徐亚威,毛云,等. 急性ST段抬高型心肌梗死伴射血分数减少型心力衰竭患者左心室逆重构的预测因素[J]. 实用医学杂志,2022,38(10):1236-1239. doi:10.3969/j.issn.1006-5725.2022.10.012
14 DERMOTT M MC, BING R. Coronary vasospasm and future percutaneous coronary intervention: relax[J]. Heart, 2022, 108(16):1253-1254. doi:10.1136/heartjnl-2022-320974
15 KOH H P, REDZUAN A MD, MOHD SAFFIAN S, et al. Mortality outcomes and predictors of failed thrombolysis following STEMI thrombolysis in a non-PCI capable tertiary hospital: a 5-year analysis[J]. Intern Emerg Med, 2023, 18(4):1169-1180. doi:10.1007/s11739-023-03202-1
16 TAO S, TANG X, YU L, et al. Prognosis of coronary heart disease after percutaneous coronary intervention: a bibliometric analysis over the period 2004-2022[J]. Eur J Med Res, 2023, 28(1):311. doi:10.1186/s40001-023-01220-5
17 GIBSON C M, AJMI I, VON KOENIG C L, et al. Pressure-controlled intermittent coronary sinus occlusion: a novel approach to improve microvascular flow and reduce infarct size in STEMI[J]. Cardiovasc Revasc Med, 2022, 45:9-14. doi:10.1016/j.carrev.2022.07.007
18 MANEMANN S M, BIELINSKI S J, MOSER E D, et al. Variability in lipid levels and risk for cardiovascular disease: an electronic health record-based population cohort study[J]. J Am Heart Assoc, 2023, 12(5):e027639. doi:10.1161/jaha.122.027639
19 SHEIKH A B, SOBOTKA P A, GARG I, et al. Blood pressure variability in clinical practice: past, present and the future[J]. J Am Heart Assoc, 2023, 12(9):e029297. doi:10.1161/jaha.122.029297
20 DONG Y, LIU X, ZHAO Y, et al. Attenuating the variability of lipids is beneficial for the hypertension management to reduce the cardiovascular morbidity and mortality in older adults[J]. Front Cardiovasc Med, 2021, 8:692773. doi:10.3389/fcvm.2021.692773
21 NAKANO S, OTAKE H, KAWAMORI H, et al. Association between visit-to-visit variability in low-density lipoprotein cholesterol and plaque rupture that leads to acute coronary syndrome[J]. Circ Rep, 2021, 3(9):540-549. doi:10.1253/circrep.cr-21-0080
22 BAUTISTA L E, RUEDA-OCHOA O L. Methodological challenges in studies of the role of blood lipids variability in the incidence of cardiovascular disease[J]. Lipids Health Dis, 2021, 20(1):51. doi:10.1186/s12944-021-01477-x
23 CHAN J S K, SATTI D I, LEE Y H A, et al. High visit-to-visit cholesterol variability predicts heart failure and adverse cardiovascular events: a population-based cohort study[J]. Eur J Prev Cardiol, 2022, 29(14):323-325.
24 NAKAJIMA A, LIBBY P, MITOMO S, et al. Biomarkers associated with coronary high-risk plaques[J]. J Thromb Thrombolysis, 2022, 54(4):647-659. doi:10.1007/s11239-022-02709-2
25 WANG X, SHAN D K, DOU G H, et al. Lipoprotein(a) is associated with coronary atheroma progression: analysis from a serial coronary computed tomography angiography study[J]. J Geriatr Cardiol, 2021, 18(12):996-1007.
26 LI S, HOU L, ZHU S, et al. Lipid variability and risk of cardiovascular diseases and all-cause mortality: a systematic review and meta-analysis of cohort studies[J]. Nutrients, 2022, 14(12):2450. doi:10.3390/nu14122450
Outlines

/